drugset / Trial / NCT03628079
A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.
Phase 1/2
Terminated
11 enrolled
Repos Pharma
Uppsala University · collabUppsala University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of mebendazole (ReposMBZ) in patient with advanced gastrointestinal cancer or cancer of unknown origin. All patients will be given ReposMBZ for 16 weeks continuous treatment, individually dosed based on the serum concentration of mebendazole.
Timeline
- Start
- 2018-05-25
- Primary completion
- 2019-01-16
- Completion
- 2019-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mebendazole | Small molecule | 50 mg | Oral |
| Subject | Mebendazole | Small molecule | 100 mg | Oral |
| Subject | Mebendazole | Small molecule | 200 mg | Oral |